NO170753C - PROCEDURE FOR THE PREPARATION OF SOLID PHARMACEUTICAL PREPARATIONS WITH DELAYED RELEASE - Google Patents

PROCEDURE FOR THE PREPARATION OF SOLID PHARMACEUTICAL PREPARATIONS WITH DELAYED RELEASE

Info

Publication number
NO170753C
NO170753C NO842766A NO842766A NO170753C NO 170753 C NO170753 C NO 170753C NO 842766 A NO842766 A NO 842766A NO 842766 A NO842766 A NO 842766A NO 170753 C NO170753 C NO 170753C
Authority
NO
Norway
Prior art keywords
pharmaceutically acceptable
compound
oral compositions
compositions
range
Prior art date
Application number
NO842766A
Other languages
Norwegian (no)
Other versions
NO842766L (en
NO170753B (en
Inventor
David R Powell
Vithal K Patel
Original Assignee
Rowell Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rowell Lab Inc filed Critical Rowell Lab Inc
Publication of NO842766L publication Critical patent/NO842766L/en
Publication of NO170753B publication Critical patent/NO170753B/en
Publication of NO170753C publication Critical patent/NO170753C/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Sliding Valves (AREA)
  • Electroplating Methods And Accessories (AREA)

Abstract

A new class of solid pharmaceutical formulations enables the attainment of slow, zero order in vivo release of a wide range of pharmaceutically active ingredients upon oral administration. A broad range of release rates can be preselected by suitable adjustments of tablet properties. The formulations are based upon control of active ingredient release from the surface of the tablet via a controlled surface erosion mechanism. These compositions comprise:(a) an effective amount in the range of 10-90 wt. % of a pharmacologically active compound having a water solubility (20' C.) of 1/5-1/1000 (w/w);(b) 1-40 wt. % of a compound which is pharmaceutically acceptable in oral compositions and has a water solubility (20° C.) of 1/1-1/40 (w/w);(c) 2-20 wt. % of a compound which is pharmaceutically acceptable in oral compositions and has a water solubility (20° C.) of 1/1-1/10 (w/w);(d) an amount in the range of 0.05-1.0 wt. % of a disintegrating agent for pharmaceutical compositions, at which amount the compound is ineffective as a disintegrating agent;(e) 0.1-2.0wt.. % of a surfactant which is pharmaceutically acceptable in oral compositions; and, as necessary for tablet manufacturing purposes;(f) 1-20 wt. % of a binder which is pharmaceutically acceptable in oral compositions; or(g) 0.5-5.0 wt. % of a die wall lubricant which is pharmaceutically acceptable in oral compositions.
NO842766A 1983-07-07 1984-07-06 PROCEDURE FOR THE PREPARATION OF SOLID PHARMACEUTICAL PREPARATIONS WITH DELAYED RELEASE NO170753C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/511,605 US4539198A (en) 1983-07-07 1983-07-07 Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range

Publications (3)

Publication Number Publication Date
NO842766L NO842766L (en) 1985-01-08
NO170753B NO170753B (en) 1992-08-24
NO170753C true NO170753C (en) 1992-12-02

Family

ID=24035636

Family Applications (1)

Application Number Title Priority Date Filing Date
NO842766A NO170753C (en) 1983-07-07 1984-07-06 PROCEDURE FOR THE PREPARATION OF SOLID PHARMACEUTICAL PREPARATIONS WITH DELAYED RELEASE

Country Status (14)

Country Link
US (1) US4539198A (en)
EP (1) EP0131485B1 (en)
AT (1) ATE55900T1 (en)
AU (1) AU561633B2 (en)
CA (1) CA1224417A (en)
DE (1) DE3483072D1 (en)
DK (1) DK162697C (en)
ES (1) ES534096A0 (en)
FI (1) FI842528A (en)
IL (1) IL72089A (en)
IT (1) IT1180193B (en)
NO (1) NO170753C (en)
NZ (1) NZ208393A (en)
ZA (1) ZA845208B (en)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57500432A (en) * 1980-03-20 1982-03-11
US4960765A (en) * 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
US4690824A (en) * 1983-07-07 1987-09-01 Redi-Rowell, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
GB8322007D0 (en) * 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
US4777049A (en) * 1983-12-01 1988-10-11 Alza Corporation Constant release system with pulsed release
US4851229A (en) * 1983-12-01 1989-07-25 Alza Corporation Composition comprising a therapeutic agent and a modulating agent
US4751071A (en) * 1983-12-01 1988-06-14 Alza Corporation Composition comprising salbutamol
DE3346571A1 (en) * 1983-12-23 1985-07-04 Bayer Ag, 5090 Leverkusen ORAL RETARDED ACETYLSALICYL ACID FORMULATIONS
IT1206166B (en) * 1984-07-26 1989-04-14 Sigma Tau Ind Farmaceuti DEVICE FOR RELEASING A SUBSTANCE IN A DISSOLUTION FLUID WITH ZERO ORDER KINETICS AND PROCEDURE FOR ITS PREPARATION
US4631305A (en) * 1985-03-22 1986-12-23 The Upjohn Company Polymeric material as a disintegrant in a compressed tablet
WO1987001936A1 (en) * 1985-09-25 1987-04-09 Gerhard Gergely Desintegration tablet and process for its manufacture
US4753801A (en) * 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
AU607690B2 (en) * 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
US6482516B1 (en) * 1993-07-20 2002-11-19 Banner Pharmacaps, Inc. Enrobed tablet
MX9300110A (en) * 1992-01-13 1994-07-29 Gerhard Gergely PHARMACEUTICAL PREPARATION IN THE FORM OF AN EFFERVESCENCE OR DISINTEGRATION TABLET OR OF AN INSTANT-TYPE GRANULATE AND PROCEDURE FOR ITS PREPARATION.
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US5609883A (en) * 1994-09-16 1997-03-11 Advanced Technology Pharmaceuticals Corporation Compressed tablet transitory lubricant system
HUP0104606A3 (en) * 1998-12-18 2003-01-28 Basf Ag A pharmaceutical mixture comprising a profen
US6726929B1 (en) 1998-12-18 2004-04-27 Basf Aktiengesellschaft Pharmaceutical mixture comprising a profen
US6210716B1 (en) 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6437000B1 (en) 1999-09-02 2002-08-20 Norstrum Pharmaceuticals, Inc. Controlled release oral dosage for suitable for oral administration
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
CA2495537C (en) 2000-08-29 2010-03-30 Nobex Corporation Immunoregulatory compounds and derivatives and methods of treating diseases therewith
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
EP1365745A2 (en) * 2001-02-15 2003-12-03 King Pharmaceuticals, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20030171436A1 (en) * 2001-10-29 2003-09-11 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
MY140809A (en) 2004-07-02 2010-01-15 Meiji Dairies Corp Solid milk and method for manufacturing thereof
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
ES2323536T3 (en) * 2004-09-01 2009-07-20 The Procter And Gamble Company COMPOSITIONS THAT INCLUDE ACID-5-AMINO-2-HYDROXIBENZOIC AND H A REDUCING SUGAR.
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
CA2620406A1 (en) 2005-09-02 2007-03-08 Genzyme Corporation Method for removing phosphate and polymer used therefore
CA2622693C (en) 2005-09-15 2015-05-05 Genzyme Corporation Sachet formulation for amine polymers
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20080075785A1 (en) * 2006-09-22 2008-03-27 San-Laung Chow Controlled release hydrogel formulation
US20110165236A1 (en) * 2006-09-22 2011-07-07 Biokey, Inc. Controlled release hydrogel formulation
EP2066293A2 (en) 2006-09-29 2009-06-10 Genzyme Corporation Amide dendrimer compositions
EP2120972A1 (en) 2006-12-14 2009-11-25 Genzyme Corporation Amido-amine polymer compositions
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
WO2009064819A2 (en) 2007-11-13 2009-05-22 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
EP2217215A1 (en) * 2007-12-14 2010-08-18 Genzyme Corporation Coated pharmaceutical compositions
EP2329823A4 (en) * 2008-09-03 2013-04-03 Takeda Pharmaceutical Method for improving absorbability of preparation, and preparation having improved absorbability
CA2765033C (en) 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
KR20130060220A (en) 2010-04-30 2013-06-07 다케다 야쿠힌 고교 가부시키가이샤 Enteric tablet
SG185081A1 (en) 2010-04-30 2012-12-28 Takeda Pharmaceutical Enteric tablet
DE102010033527A1 (en) 2010-08-05 2012-02-09 Acino Pharma Ag Quetiapine tablets
EP2425826A1 (en) 2010-09-01 2012-03-07 Disphar International B.V. Mesalazine tablet having improved dissolution
DE102011115690A1 (en) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapine-containing formulations
ITUA20162293A1 (en) 2016-04-05 2017-10-05 Sofar Spa Process for solid formulations of mesalazine
EP3662898A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361545A (en) * 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
US4264573A (en) * 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
FR2471186A1 (en) * 1979-12-10 1981-06-19 Roussel Uclaf NEW COLIC DELITESCENCE TABLETS AND THEIR PREPARATION PROCESS
JPS57500432A (en) * 1980-03-20 1982-03-11

Also Published As

Publication number Publication date
NO842766L (en) 1985-01-08
CA1224417A (en) 1987-07-21
DK162697C (en) 1992-04-21
NO170753B (en) 1992-08-24
ES8600053A1 (en) 1985-10-01
FI842528A (en) 1985-01-08
DK162697B (en) 1991-12-02
ATE55900T1 (en) 1990-09-15
US4539198A (en) 1985-09-03
DK333884D0 (en) 1984-07-06
DE3483072D1 (en) 1990-10-04
FI842528A0 (en) 1984-06-21
EP0131485B1 (en) 1990-08-29
DK333884A (en) 1985-01-08
AU561633B2 (en) 1987-05-14
NZ208393A (en) 1987-03-31
ZA845208B (en) 1985-03-27
IT8421720A0 (en) 1984-07-02
IL72089A0 (en) 1984-10-31
EP0131485A3 (en) 1986-08-06
IT8421720A1 (en) 1986-01-02
AU2889884A (en) 1985-01-10
IL72089A (en) 1987-09-16
EP0131485A2 (en) 1985-01-16
IT1180193B (en) 1987-09-23
ES534096A0 (en) 1985-10-01

Similar Documents

Publication Publication Date Title
NO170753C (en) PROCEDURE FOR THE PREPARATION OF SOLID PHARMACEUTICAL PREPARATIONS WITH DELAYED RELEASE
IL111647A (en) Pharmaceutical compositions comprising microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles and their preparation
YU13695A (en) Application of 2-phenyl-3-aroylbenzothiophene and pharmaceutical formulations thereof
DK0385582T3 (en) Nifedipine-containing pharmaceutical compositions and processes for their preparation
FI945081A (en) Stable hydrated cephalosporin dry powder for oral suspension formulation
BG105436A (en) Pharmaceutical compositions comprising entacapone or nitecapone as well as a cross-linked cellulpse derivative
CA2136404A1 (en) Mucoadhesive, therapeutic or hygienic solid composition for application on oral or nasal mucosa
GB1418208A (en) Pharmaceutical compositions
IL102814A0 (en) Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them
HUP0103431A2 (en) Pharmaceutical, oral compositions containing 5-ht4 agonists or antagonists as active agent
IE894049L (en) Therapeutically active substituted benzimidazole and process¹for its preparation
FI921809A (en) FOERFARANDE FOER FRAMSTAELLNING AV EN TABLETT- ELLER DRAGEKOMPOSITION, SOM INNEHAOLLER EN FOER VAERME, LJUS OCH FUKTIGHETKAENSLIG AKTIV INGREDIENS MED MONOKLINISK KRISTALLSTRUKTUR.
FI850828A0 (en) NYA (8S) -8 -FLUOROERYTROMYCINDERIVAT, FOERFARANDE FOER FRAMSTAELLNING AV DESSA OCH PHARMACEUTISKA SAMMANSAETTNINGAR INNEHAOLLANDE DEM.
ATE327742T1 (en) TWO-PHASE COMPOSITION WITH TRAMADOL
GB1354451A (en) Halogen-substituted phenyl-alkylamines and their derivatives
KR910019625A (en) How to suppress bone mineral loss
Kiesel et al. Prevention of diabetes in BB rats by an E. coli extract(OM-89)
KR910002455A (en) Pharmaceutical compositions containing acrylic acid derivatives and their use as medicaments
ES342394A1 (en) Novel Benzylaminoimidazoline Derivatives, the preparation thereof and Compositions containing the same
GB1478020A (en) Composition for the treatment of asthma
TH59782A3 (en) Controlled release galantamine mixtures
JO1653B1 (en) Benzimidazole process for its preparation
KR960007619A (en) Novel alginic acid derivatives and preparation method thereof
HUT59597A (en) Process for producing pharmaceutical compositions contaiing pharmaceutically active tetrahydro-naphtalene derivatives

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN JANUARY 2001